Full-Time

Senior Manager

IT Infrastructure

Freenome

Freenome

201-500 employees

Blood-based multiomics cancer detection tests

Compensation Overview

$181k - $232.6k/yr

+ Equity + Bonus

Daly City, CA, USA

Hybrid

Category
DevOps & Infrastructure (2)
,
Required Skills
Computer Networking
VMWare
Google Cloud Platform
Requirements
  • 7+ years’ experience in a technology leadership/management role.
  • Strong management and technical skills, most notably architect-level skills in virtualization, systems administration, scalable upgrade and migration strategies, networking, and storage. Possess the technical expertise with virtualization and network infrastructure technologies such as VMware vSphere, LAN and WAN.
  • 5+ years of experience managing or maintaining enterprise IT infrastructure (Network, IaaS, PaaS, and/or Security).
  • Experience in a continuous improvement environment with a track record of achieving significant continual development.
  • Strong project management, problem solving, organizational, relationship, communication, and negotiation skills (oral and written) are required.
  • 7+ years of experience with Windows 10/11, Windows server, DAS/NAS/SAN, Google workspace, and GCP.
  • Strong knowledge of security access controls, policies, groups, rights, and permissions.
  • Familiarity with IT GRC (BCDR, ITSM/ITIL, SOX, ISO, PCI, HIPAA, GMP, GDPR, FDA 21 CFR Part 11).
  • Ability to document and explain complex technical solutions to management and other non-technical staff.
  • Strong customer service and time management skills, with the ability to work effectively in a dynamic, and fast-paced environment.
  • Flexibility to work weekends and after hours for IT projects/maintenance (on occasion).
Responsibilities
  • Leads team of network engineers, system administrators, lab system administrators to support Freenome infrastructure (On prem, Labs and GCP).
  • Problem Solving, collaboration, solid comprehension of cloud, virtualization, storage, networking, software and hardware, strategic planning, leadership, mentorship, creating and giving presentations.
  • Identify, create, and apply process improvement to increase product and service quality to achieve business objectives.
  • Contributes to defining the department's long-term strategy and goals.
  • Collaborate with the Help desk and Business Application team to define and implement the infrastructure needed for day to day operations.
  • Ensures data security and disaster recovery protocols are in place. Ensuring compliance with regulatory requirements.
  • Develops and creates standardized processes and procedures to guide documentation and knowledge base development for IT infrastructure operations support.
  • Develops and supports standards for enterprise-wide use of resources. Recommends enterprise level strategies and goals for infrastructure hardware and software procurement and deployment. Writes detailed scopes of work for staff projects.
  • Plan, communicate, and deploy changes to IT infrastructure per standard change management process and scheduled maintenance windows. Coordinate IT change and maintenance activities with business stakeholders.
  • Maintains IT infrastructure and network diagrams, asset/equipment inventory and IT change/incident logs.
  • Supports IT audits and conduct IT systems/network vulnerability scanning, patching and hardening.
  • Manage external vendor relationships.
Desired Qualifications
  • Bachelor's degree in MIS/CIS, Computer Science or equivalent professional experience.
  • Industry certifications such as ITIL, CCNA, MCITP, MCSA, MCSE, VCP, Cloud+, Security+ preferred.
  • Experience with GMP systems and IT systems change management process.
  • Experience with Juniper, Meraki, Netapp, VmWare, and Google workspace.

Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
  • SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
  • Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.

What critics are saying

  • Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
  • SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
  • Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.

What makes Freenome unique

  • Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
  • Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
  • Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Freenome who can refer or advise you

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-3%
BioPharma Dive
Nov 20th, 2025
Roche inks deal for rights to Freenome cancer tests outside US

Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."

Freenome
Nov 19th, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]

finanzen.net
Nov 18th, 2025
Freenome, Roche Partner in $200M Deal

Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.

PR Newswire
Jun 2nd, 2025
Freenome Announces Jama Publication Of Data From Pivotal Study Of Its Blood-Based Test For Colorectal Cancer

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw

Health Technology Insights
May 21st, 2025
Freenome Appoints Linh H. Le as Chief Financial Officer

Freenome appoints Linh H. Le as chief financial officer.